Short-term efficacy and safety of nedaplatin versus cisplatin combined with gemcitabine for treatment of advanced lung squamous cell carcinoma: A systematic review and meta-analysis_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

CHENG Tao ^1,2 , JIN Dacheng ² , CUI Baiqiang ^1,2 , HUANG Daxin ^1,2 ,  GOU Yunjiu ²

1. The First Clinical Department of Gansu University of Traditional Chinese Medicine, Lanzhou, 730000, P. R. China;
2. Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, 730000, P. R. China;

Corresponding author：

GOU Yunjiu, Email: gouyunjiu@163.com

Keywords：

Nedaplatin; cisplatin; gemcitabine; advanced lung squamous cell carcinoma; systematic review/meta-analysis

DOI：

10.7507/1007-4848.202202023

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the short-term efficacy and safety of nedaplatin combined with gemcitabine compared with cisplatin combined with gemcitabine in the treatment of advanced lung squamous cell carcinoma. Methods The Cochrane Library, EMbase, PubMed, Web of Science, Wanfang, VIP, CNKI and China General Library of Biomedical Literature were searched. Literatures related to the efficacy and safety of nedaplatin combined with gemcitabine (nedaplatin group) versus cisplatin combined with gemcitabine (cisplatin group) in the treatment of advanced lung squamous cell carcinoma published from the inception to October 2021 were searched. The quality of included studies was assessed by Cochrane bias assessing tool and the meta-analysis was conducted by using RevMan 5.4. Results A total of 10 articles were included covering 914 patients. Meta-analysis showed that the objective remission rate (OR=1.51, 95%CI 1.13-2.01, P=0.005), disease control rate (OR=1.54, 95%CI 1.10-2.15, P=0.01) and 1-year survival rate (OR=2.29, 95%CI 1.25-4.18, P=0.007) of the nedaplatin group were better than those of the cisplatin group. In terms of side effects, the incidence of white blood cell and hemoglobin decline, nausea and vomiting, and diarrhea in the nedaplatin group was lower than that in the cisplatin group (P≤0.05). The differences in the platelet decline and liver and kidney damage between the two groups were not statistically significant (P>0.05). Conclusion For patients with advanced lung squamous cell carcinoma, the short-term efficacy of nedaplatin combined with gemcitabine may be better than cisplatin combined with gemcitabine, and the incidence of adverse reactions is lower.

Citation： CHENG Tao, JIN Dacheng, CUI Baiqiang, HUANG Daxin, GOU Yunjiu. Short-term efficacy and safety of nedaplatin versus cisplatin combined with gemcitabine for treatment of advanced lung squamous cell carcinoma: A systematic review and meta-analysis. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(11): 1638-1644. doi: 10.7507/1007-4848.202202023 Copy

1.	International Agency for Research on Cancer. Global cancer observatory: Cancer today. World Health Organization. https://gco. iarc. fr/today (accessed Janyary 19, 2020: ).
2.	Yang QF, Wu D, Wang J, et al. Development and validation of an individualized immune prognostic model in stageⅠ-Ⅲlung squamous cell carcinoma. Sci Rep, 2021, 11(1): 12727.
3.	张家豪, 张亚杰, 李鹤成. 2020年V1版《NCCN非小细胞肺癌临床实践指南》更新解读. 中国胸心血管外科临床杂志, 2020, 27(6): 614-618.
4.	Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs. chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial. JAMA Oncol, 2021, 7(5): 709-717.
5.	Zhou C, Wu L, Fan Y, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol, 2021, 16(9): 1501-1511.
6.	Reck M, Shankar G, Lee A, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expert Rev Respir Med, 2020, 14(2): 125-136.
7.	Kawashima Y, Harada T, Fujita Y, et al. Randomized phaseⅡtrial of carboplatin+nab-paclitaxel versus cisplatin+gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan Lung Cancer Study Group 1302. Int J Clin Oncol, 2021, 26(3): 515-522.
8.	Choi JH, Choi J, Chung SM, et al. The clinical efficacy and safety of four-weekly docetaxel as first-line therapy in elderly lung cancer patients with squamous cell carcinoma. Tuberc Respir Dis (Seoul), 2019, 82(3): 211-216.
9.	Grossi F, Jaśkiewicz P, Ferreira M, et al. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: A prospective randomized international phaseⅡstudy (NAVoTrial 03). Ther Adv Med Oncol, 2021, 13: 17588359211022905.
10.	Halvorsen TO, Stokke K, Killingberg KT, et al. Randomized phaseⅢtrial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. Acta Oncol, 2020, 59(9): 1051-1057.
11.	Taniguchi H, Yamaguchi H, Dotsu Y, et al. PhaseⅡstudy of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. Thorac Cancer, 2019, 10(9): 1764-1769.
12.	黄大新, 韩松辰, 金大成, 等. 奈达铂对比顺铂联合氟尿嘧啶治疗食管癌疗效和安全性的系统评价与Meta分析. 中国胸心血管外科临床杂志, 2022, 29(11): 1511-1516.
13.	Fu J, Fang S, Wen Y, et al. The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer. J Buon, 2020, 25(4): 1707-1713.
14.	Lv WZ, Lin Z, Wang SY, et al. PhaseⅡstudy of a bi-weekly chemotherapy regimen of combined liposomal paclitaxel and nedaplatin for the treatment of advanced squamous cell lung cancer. Transl Oncol, 2019, 12(4): 656-660.
15.	陈胜佳, 朱凯, 林金兰, 等. 奈达铂联合吉西他滨对比顺铂联合吉西他滨一线治疗晚期肺鳞癌随机对照临床研究. 中国医药科学, 2021, 11(4): 5-8, 46.
16.	曹子肖, 周丽亚, 刘佳慧, 等. 吉西他滨联合奈达铂治疗晚期肺鳞癌的近期疗效观察. 蚌埠医学院学报, 2021, 46(4): 475-479.
17.	赵淑芬, 肖文静, 刘宁, 等. 吉西他滨联合奈达铂治疗晚期肺鳞癌患者的疗效分析. 中国实用医药, 2016, 11(11): 124-125.
18.	舒诚荣, 曹爱玲. 吉西他滨联合奈达铂治疗晚期肺鳞癌34例疗效观察. 海南医学, 2014, (13): 1970-1972.
19.	陈泽勉. 晚期肺鳞癌采取奈达铂与顺铂结合吉西他滨化疗的效果对比分析. 北方药学, 2019, 16(7): 15-16.
20.	张容轩. 西他滨分别联合顺铂和奈达铂治疗晚期肺鳞癌的疗效及安全性分析. 临床合理用药, 2017, 10(11): 46-48.
21.	张晶, 陈群, 柯明耀, 等. 奈达铂联合吉西他滨与顺铂联合吉西他滨一线治疗晚期肺鳞癌随机对照临床研究. 国际肿瘤学杂志, 2017, 44(1): 15-18.
22.	罗小宁, 张羽, 郭蒸. 吉西他滨联合奈达铂治疗晚期肺鳞癌的临床疗效观察. 中国现代医生, 2020, 58(27): 118-120, 124.
23.	张蕾, 张敬伟, 王羽喆. 吉西他滨联合奈达铂治疗晚期肺鳞癌的临床观察. 当代医学, 2014, (26): 141-142.
24.	晏军, 曹纯. 吉西他滨联合奈达铂治疗晚期肺鳞癌的疗效观察. 四川医学, 2017, 38(2): 199-201.
25.	Gao M, Zhou Q. Progress in treatment of advanced squamous cell lung cancer. Zhongguo Fei Ai Za Zhi, 2020, 23(10): 866-874.
26.	Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem, 2019, 88: 102925.
27.	Qi L, Luo Q, Zhang Y, et al. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol, 2019, 32(8): 1469-1486.
28.	Paroha S, Verma J, Dubey RD, et al. Recent advances and prospects in gemcitabine drug delivery systems. Int J Pharm, 2021, 592: 120043.
29.	Ikeda S, Yoshioka H, Kaneda T, et al. A phaseⅡstudy of cisplatin plus gemcitabine followed by maintenance gemcitabine for advanced squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group 1302. Oncology, 2019, 97(6): 327-333.
30.	Yue J, Hu NL, Wang X, et al. Evaluation of the efficacy and safety of combination of gemcitabine and nedaplatin for patients with HER-2 negative metastatic breast cancer. Zhonghua Zhong Liu Za Zhi, 2021, 43(8): 883-888.
31.	Lu S, Chen Z, Hu C, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung—A multicenter, open-label, randomized, phase Ⅲ trial. J Thorac Oncol, 2018, 13(11): 1743-1749.
32.	徐赟, 卫立辛. 吉西他滨联合奈达铂治疗的非小细胞肺癌患者血清CDA水平变化及意义. 中国医院药学杂志, 2019, 39(24): 2537-2541.
33.	陈永倖, 符诒慧, 蒙冲. 吉西他滨联合奈达铂一线治疗晚期非小细胞肺癌的临床疗效及安全性评价. 临床内科杂志, 2019, 36(7): 476-478.
34.	房辉, 许淑云, 汤莹, 等. 吉西他滨联合奈达铂治疗晚期肺癌患者的效果分析. 肿瘤药学, 2019, 9(2): 296-299.
35.	Li CH, Liu MY, Liu W, et al. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 2014, 15(2): 731-736.
36.	Shan J, Xiong Y, Wang D, et al. Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer. Mol Clin Oncol, 2015, 3(3): 543-549.
37.	Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): A randomised, open-label, phase 3 trial. Lancet Oncol, 2015, 16(16): 1630-1638.
38.	胡永梅, 张浩玲, 何霞, 等. 奈达铂或顺铂联合紫杉醇治疗晚期非小细胞肺癌和食管癌的系统评价. 中国药房, 2016, 27(24): 3397-3400.

1. International Agency for Research on Cancer. Global cancer observatory: Cancer today. World Health Organization. https://gco. iarc. fr/today (accessed Janyary 19, 2020: ).
2. Yang QF, Wu D, Wang J, et al. Development and validation of an individualized immune prognostic model in stageⅠ-Ⅲlung squamous cell carcinoma. Sci Rep, 2021, 11(1): 12727.
3. 张家豪, 张亚杰, 李鹤成. 2020年V1版《NCCN非小细胞肺癌临床实践指南》更新解读. 中国胸心血管外科临床杂志, 2020, 27(6): 614-618.
4. Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs. chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial. JAMA Oncol, 2021, 7(5): 709-717.
5. Zhou C, Wu L, Fan Y, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol, 2021, 16(9): 1501-1511.
6. Reck M, Shankar G, Lee A, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expert Rev Respir Med, 2020, 14(2): 125-136.
7. Kawashima Y, Harada T, Fujita Y, et al. Randomized phaseⅡtrial of carboplatin+nab-paclitaxel versus cisplatin+gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan Lung Cancer Study Group 1302. Int J Clin Oncol, 2021, 26(3): 515-522.
8. Choi JH, Choi J, Chung SM, et al. The clinical efficacy and safety of four-weekly docetaxel as first-line therapy in elderly lung cancer patients with squamous cell carcinoma. Tuberc Respir Dis (Seoul), 2019, 82(3): 211-216.
9. Grossi F, Jaśkiewicz P, Ferreira M, et al. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: A prospective randomized international phaseⅡstudy (NAVoTrial 03). Ther Adv Med Oncol, 2021, 13: 17588359211022905.
10. Halvorsen TO, Stokke K, Killingberg KT, et al. Randomized phaseⅢtrial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. Acta Oncol, 2020, 59(9): 1051-1057.
11. Taniguchi H, Yamaguchi H, Dotsu Y, et al. PhaseⅡstudy of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. Thorac Cancer, 2019, 10(9): 1764-1769.
12. 黄大新, 韩松辰, 金大成, 等. 奈达铂对比顺铂联合氟尿嘧啶治疗食管癌疗效和安全性的系统评价与Meta分析. 中国胸心血管外科临床杂志, 2022, 29(11): 1511-1516.
13. Fu J, Fang S, Wen Y, et al. The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer. J Buon, 2020, 25(4): 1707-1713.
14. Lv WZ, Lin Z, Wang SY, et al. PhaseⅡstudy of a bi-weekly chemotherapy regimen of combined liposomal paclitaxel and nedaplatin for the treatment of advanced squamous cell lung cancer. Transl Oncol, 2019, 12(4): 656-660.
15. 陈胜佳, 朱凯, 林金兰, 等. 奈达铂联合吉西他滨对比顺铂联合吉西他滨一线治疗晚期肺鳞癌随机对照临床研究. 中国医药科学, 2021, 11(4): 5-8, 46.
16. 曹子肖, 周丽亚, 刘佳慧, 等. 吉西他滨联合奈达铂治疗晚期肺鳞癌的近期疗效观察. 蚌埠医学院学报, 2021, 46(4): 475-479.
17. 赵淑芬, 肖文静, 刘宁, 等. 吉西他滨联合奈达铂治疗晚期肺鳞癌患者的疗效分析. 中国实用医药, 2016, 11(11): 124-125.
18. 舒诚荣, 曹爱玲. 吉西他滨联合奈达铂治疗晚期肺鳞癌34例疗效观察. 海南医学, 2014, (13): 1970-1972.
19. 陈泽勉. 晚期肺鳞癌采取奈达铂与顺铂结合吉西他滨化疗的效果对比分析. 北方药学, 2019, 16(7): 15-16.
20. 张容轩. 西他滨分别联合顺铂和奈达铂治疗晚期肺鳞癌的疗效及安全性分析. 临床合理用药, 2017, 10(11): 46-48.
21. 张晶, 陈群, 柯明耀, 等. 奈达铂联合吉西他滨与顺铂联合吉西他滨一线治疗晚期肺鳞癌随机对照临床研究. 国际肿瘤学杂志, 2017, 44(1): 15-18.
22. 罗小宁, 张羽, 郭蒸. 吉西他滨联合奈达铂治疗晚期肺鳞癌的临床疗效观察. 中国现代医生, 2020, 58(27): 118-120, 124.
23. 张蕾, 张敬伟, 王羽喆. 吉西他滨联合奈达铂治疗晚期肺鳞癌的临床观察. 当代医学, 2014, (26): 141-142.
24. 晏军, 曹纯. 吉西他滨联合奈达铂治疗晚期肺鳞癌的疗效观察. 四川医学, 2017, 38(2): 199-201.
25. Gao M, Zhou Q. Progress in treatment of advanced squamous cell lung cancer. Zhongguo Fei Ai Za Zhi, 2020, 23(10): 866-874.
26. Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem, 2019, 88: 102925.
27. Qi L, Luo Q, Zhang Y, et al. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol, 2019, 32(8): 1469-1486.
28. Paroha S, Verma J, Dubey RD, et al. Recent advances and prospects in gemcitabine drug delivery systems. Int J Pharm, 2021, 592: 120043.
29. Ikeda S, Yoshioka H, Kaneda T, et al. A phaseⅡstudy of cisplatin plus gemcitabine followed by maintenance gemcitabine for advanced squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group 1302. Oncology, 2019, 97(6): 327-333.
30. Yue J, Hu NL, Wang X, et al. Evaluation of the efficacy and safety of combination of gemcitabine and nedaplatin for patients with HER-2 negative metastatic breast cancer. Zhonghua Zhong Liu Za Zhi, 2021, 43(8): 883-888.
31. Lu S, Chen Z, Hu C, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung—A multicenter, open-label, randomized, phase Ⅲ trial. J Thorac Oncol, 2018, 13(11): 1743-1749.
32. 徐赟, 卫立辛. 吉西他滨联合奈达铂治疗的非小细胞肺癌患者血清CDA水平变化及意义. 中国医院药学杂志, 2019, 39(24): 2537-2541.
33. 陈永倖, 符诒慧, 蒙冲. 吉西他滨联合奈达铂一线治疗晚期非小细胞肺癌的临床疗效及安全性评价. 临床内科杂志, 2019, 36(7): 476-478.
34. 房辉, 许淑云, 汤莹, 等. 吉西他滨联合奈达铂治疗晚期肺癌患者的效果分析. 肿瘤药学, 2019, 9(2): 296-299.
35. Li CH, Liu MY, Liu W, et al. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 2014, 15(2): 731-736.
36. Shan J, Xiong Y, Wang D, et al. Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer. Mol Clin Oncol, 2015, 3(3): 543-549.
37. Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): A randomised, open-label, phase 3 trial. Lancet Oncol, 2015, 16(16): 1630-1638.
38. 胡永梅, 张浩玲, 何霞, 等. 奈达铂或顺铂联合紫杉醇治疗晚期非小细胞肺癌和食管癌的系统评价. 中国药房, 2016, 27(24): 3397-3400.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Short-term efficacy and safety of nedaplatin versus cisplatin combined with gemcitabine for treatment of advanced lung squamous cell carcinoma: A systematic review and meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content